Plan Your Care: Advance Directives on National Healthcare Decisions Day
National Healthcare Decisions Day is observed annually on April 16 to encourage adults to plan for their future healthcare through advance directives. The 2026 initiative is to normalize, promote, and encourage the use of advance care planning and directive documents.
Stenting Advances Treatment for Post‑thrombotic Syndrome
Stenting for Post-Thrombotic Syndrome — A Step Forward {Editorial} [Apr 13, 2026] Flumignan & Nakano @NEJM https://t.co/w559CHaTON #NCT03250247 #VTE
Endovascular Therapy Shows Promise for Post‑Thrombotic Syndrome
Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial [Apr 13, 2026] Vedantham et al. for the C-TRACT [Chronic Venous Thrombosis: Relief with Adjunctive Catheter-Directed Therapy] Trial Investigators @NEJM https://t.co/Ayd4Fa0ARl #NCT03250247 #VTE https://t.co/6iD1NUQdgX
Accelerated Biological Aging Raises Dementia Risk in Women
Epigenetic Clocks of Biological Aging and Risk of Incident Mild Cognitive Impairment and Dementia: The Women's Health Initiative Memory Study "In this cohort study of older women, accelerated biological aging measured by AgeAccelGrim2 was associated with higher risk of incident MCI/probable...
Americans Trust Career Scientists Over Agency Leaders
Stark Divide: Americans More Confident in Career Scientists at U.S. Health Agencies Than Leaders A new survey by the Annenberg Public Policy Center finds that 67% of Americans have confidence in career scientists working at U.S. federal health agencies, compared with...
NY Home Care Workers Hunger Strike Over 24‑Hour Shifts
Home care workers in New York are set to begin a hunger strike on Thursday as they fight to ban 24-hour shifts. The city and state seem prepared to wait it out, as Hochul and Mamdani work behind the scenes...
Menopause Hormone Therapy May Influence Triple‑negative Breast Cancer Risk
Amen. I wrote about this in detail in my Substack about Triple Negative Breast Cancer and Menopause Hormone Therapy: https://open.substack.com/pub/drjordanemont/p/cancer-cases-triple-negative-breast?utm_campaign=post-expanded-share&utm_medium=post%20viewer
Healthcare Splits: MedTech Down, Biotech Outperforms Amid Rising Rates
Despite SPX back at new highs, Healthcare has proven dismal this year, & the bifurcation in this sector w/ Med Tech turning down while Biotech outperforms is not dissimilar w/ what happened in Technology early in the year. Given my expectations...
Don't Trust Unqualified Influencers; Demand Real Expertise
The PTs are lying to you. The surgeons are lying to you. The certifications are lying to you. But the guy with 40k followers doing band exercises in his garage? The influencer who made a $29 pain program over a weekend?...
New Trial Compares Dara‑Bor‑Dex vs Cy‑Bor‑Dex in Myeloma‑Induced Kidney
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/KJfqVVcwEr
Daratumumab Boosts Revlimid Efficacy in Smoldering Myeloma
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/SKPUQiSaU4
Phase 3 Trial Tests Daratum
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/Hq9VlRCTCI
Four Candidates Target Ultra‑Rare Polish PUS3 Syndrome
“We have four drug candidates for patients with an ultra-rare disease with Polish origins, the PUS3 syndrome; one of these candidates will be used in practice,” Lisowski said. https://t.co/GTJbPQSdXQ
When to Stop Myeloma Treatment: MRD Insights
MT @hhashmi87 #IMS25 Great Meet The Expert talk by @bdermanmd on MRD in Myeloma Risk vs benefit Who can stop treatment Active surveillance post discontinuation #mmMRD #mmsm https://t.co/FIDPrE7QRb
MRD‑negative Patients May Stop Myeloma Maintenance Therapy
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) - @bdermanmd et al. @ajjakubowiak #ASCO24 Abstract 106 https://t.co/FBTY7SnCxK #NCT04108624 #mmsm #mmMRD
ODAC Approves MRD as Early Endpoint for Myeloma Trials
A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma https://t.co/eDOgIrpVeR #mmMRD #mmsm #ctsm @FDAOncology https://t.co/V4wrNgvTrG
Clinicians Show Mixed Adoption of Myeloma MRD Testing
Clinician attitudes and practices toward measurable residual disease in multiple myeloma [Jun 7, 2020] @bdermanmd @jagoda_jasielec @ajjakubowiak Brit J Haematol https://t.co/8zhxYfYwZQ #mmsm #mmMRD https://t.co/mPtRCjnB9f
Vaccines Vanishing Threatens Global Health Catastrophe
The Horrors That Could Lie Ahead if Vaccines Vanish — @propublica good article on the work of @NathanLo3579 @Stanford my former mentee and amazing colleague https://t.co/n9oUgkvOZ7
Glioblastoma's Immune Microenvironment Blocks Checkpoint Therapy
The glioblastoma tumor immune microenvironment (TIME) is an immunosuppressive barrier to therapy that encumbers glioblastoma responses to immune checkpoint inhibition (ICI). https://t.co/rgIKZ8N0Q4
Rethinking Healthcare: Julie Yoo on Infinite Growth
I really enjoyed interviewing @a16z 's @julieyoo : Rethinking the Rules: Julie Yoo on Infinite Healthcare, Compound Businesses, and the New Investor Playbook https://t.co/fdIq6NbQ7b cc @startuphealth
Gut Microbiome Fuels Worse Infections in Fatty Liver
Alterations in the gut microbiome significantly worsen bacterial infection outcomes in fatty liver disease by increasing liver damage and inflammation, highlighting the gut–liver axis as a potential target for new therapies. guthealth
Primary Care's Heart: Connection, Stories, and Human Agency
Lovely final ep of @LisaRosenbaum17's perceptive @NEJM NOS pcast series on primary care: https://t.co/vYhK3QN5ce Ep has it all for me: agency, SDT, call of stories, limitations of metrics, value of connection & longitudinal relationships; cx of medicine; warmth; love. @zakkohane
Bergamottin Reduces Cancer‑related Cachexia via Multiple Pathways
A Novel Role of Bergamottin in Attenuating Cancer Associated Cachexia by Diverse Molecular Mechanisms https://t.co/pr3d4kg0hB #mdpicancers
Early GLP‑1 Rodent Studies Showed Weight Loss Before Diabetes Focus
I don't think this is correct from @nytimes op-ed on GLP-1s - wt loss known from early rodent studies involving injection into CSF as I recall. DM2 more tractable as initial pharma indication, esp at that time - many still...
New NEJM Review Links Hormone Therapy to Cardiovascular Risk
Sex hormones, clotting disorders, and cardiovascular risk An important new @NEJM review for MHT and testosterone latest data https://t.co/UNqXAwjsKM https://t.co/4ckJsc4YyE
Molift Raiser Pro Delivers High-Capacity Assistance in Confined Spaces
Molift Raiser Pro: High-Capacity Stand-Up Assistance in Tight Spaces by @gigadgets_ #MedTech #Healthcare #HealthTech #Tech #TechForGood https://t.co/vumqKwh3lm
FDA Reverses Ban on 12 Peptides for Review
So... @SecKennedy just announced that 12 peptides the Biden FDA shoved into "Category 2" — effectively banning them from regulated compounding pharmacies and driving people to the black market - are being pulled back for legitimate scientific review. Here's what each one...
Patients Choose Risky Care When Health Systems Fail
I don’t think patients want ChatGPT or an AI doctor startup to replace their health system - but when you’re desperate, you’ll take what you can get - the safety and efficacy be damned. So if health systems don’t fill...
Retatrutide Poised to Become History’s Biggest Drug
Not s hot take, but I think retatrutide could be the largest drug in history @TravisHoium makes a great case on why the best way to play the emerging peptide market is $HIMS
Aging Autistics: Higher Health Risks and Potential Benefits
How do autistic people age — and what does it mean for their health? Most research on autism focuses on younger people, but some studies suggest older adults face increased risks — and perhaps benefits. https://t.co/3YAztmYqGh https://t.co/VKdej4ke2Y
Engineered Brain Cells Erase Alzheimer’s Proteins in Mice
Enhanced brain cells clear away dementia-related proteins New cellular immunotherapy approach for Alzheimer’s disease shows promise in mice https://t.co/YBoqUZLvJo https://t.co/FjG699Etga
Medicare Already Funds Universal Care, Not Insurers
Your “who’s gonna pay for universal healthcare” gotcha isn’t actually a gotcha. Here’s why from AOC. — We’ve paid for universal Medicare twice over. We’re just giving all the money to for-profit health insurers like United Healthcare. In exchange we all...
Discover Cutting‑Edge Stem Cell Advances at BEYOND 2026
The best place to learn about the latest stem cell research is at BEYOND, Austin, TX, May 27-29, 2026. Learn all the new ways stem cell research is growing and becoming more available from @stemcellchristian at the BEYOND Biohacking Conference. https://t.co/e04Xnfyjwa
Speedy Fixes: Removing Customer Roadblocks Drives Success
The CEO of UnitedHealthcare on Fixing What Frustrates Customers Most https://t.co/WWzA25AjwY The best organizations know how to move fast and remove roadblocks when it matters the most. #customerunderstanding #customerexperience https://t.co/fAADxWax0B
Doctor Cuts GLP‑1 After Low BMI, Dosage Adjusted
Quick update on the GLP-1s: Doctor told me yesterday to get off it, BMI (19.2) too low. Was always on the lowest dose of Zepbound, so will cut that in half (0.5 x 2.5mg) and space out (7 -> 10 -> 14...
Promolytics: Targeting Cancer‑Promoting Clones to Halt Progression
A new review on tumor promotion and the evolution of cancer with the concept of "promolytics" —drugs that could prevent potentially dangerous clones and/or their progression https://t.co/IFah5gi8ZK @Nature
New Market Map Highlights Agentic AI in Ambulatory Sector
Market maps have become a real focus of ours as LLMs are getting company categorization so wrong. Our latest, in partnership with Confido Health & @RMFnyc1, focuses on agentic AI for the ambulatory market. What's being deployed now? Our focus...
Booster Speed-Processing Training Cuts Dementia Risk 25%
This one type of cognitive training might delay dementia.🧠🧠 In the ACTIVE randomized controlled trial, older adults were assigned to memory, reasoning, or speed training — then they were followed for 20 years. Standard memory and reasoning training didn't reduce dementia risk....
Former FDA Chief Urges Term Limits, Merit‑based Appointments
Former FDA cancer chief/CDER dir. Rick Pazdur told me earlier this week he's concerned w/political appointees injecting themselves into drug reviews - and that this might trickle down past this admin. He's calling for time limits on senior FDA positions...
From $17M to Global Tiger Cub Healthcare Giant
This sell-side pharma equity analyst started with $17M. He built one of the world’s largest Tiger Cub healthcare funds.
Moderna's Cancer Therapy Rename May Mislead Physicians
Moderna mRNA cancer treatment used to be called a "cancer vaccine" but in 2023 they switched to "individualized neoantigen therapy." Some docs think the name change is misleading. https://t.co/UIn2djdDAv
AI Agents Power Future Biotech Labs and Organizations
Live in 15 minutes — I'm talking with Stanford's @james_y_zou on his latest research in building laboratories and biotech orgs made of hundreds or even thousands of AI agents Register now to watch live, for free: https://t.co/xSa5NXkX4A
Statins Don't Harm Muscle Health in Older Adults
Statin use does not impair muscle health in older adults: findings from the SCOPE study https://t.co/WKjk9Ov0rG https://t.co/xTo9mk3vbw
Chinese Biotechs Lead Licensing as M&A Surges
M&A is sizzling right along, with the Q1 numbers looking good for biotech. IPOs got started on the year with a spike in offerings and some mixed results on the Street. Dealmaking remains solid. And shall we just call it...
FDA Peptide Meeting Signals $100B Market Boom
I wish this FDA meeting to discuss peptides was happening a little sooner but I'm glad it's finally on the calendar so we don't have to keep guessing. Looks like they're going to start with 7 peptides (BPC-157, TB-500, KPV, Mots-C,...
Inflammation: The Overlooked Key to Preventing CAD
That's right. Inflammation is the big miss for getting ahead of coronary artery disease https://t.co/KIs1AFxflE My review of this big shift https://t.co/foSaaTYUD4 https://t.co/cCRqSd8axt
GLP‑
This is nonsense. GLP1’s produce weight loss, about 1/4 of that is lean mass, which itself is not all muscle. Muscle quality (force production relative to size) improves with GLP1 use, which means more strength in a group of people...
Evening Workouts Boost Lasting Blood Sugar Control
For people with Type 2 diabetes, exercise later in the day tends to result in substantial and lasting improvements to blood sugar control. https://t.co/xO87XFTdQ4
Medical AI Flaws Exposed: Bad Chatbot Answers, Unreliable Data
Issues recognized with medical AI models —Problematic responses to 5 chatbots https://t.co/V6IZHOhAm4 —Prediction based on unreliable, open-access datasets https://t.co/PnJ0TrtXK2 https://t.co/Bp8ztckFgV
FDA Panel to Consider Expanding Peptide Access
FDA panel will meet to discuss allowing broader access to certain peptides https://t.co/PDWKvmvvUH via @LizzyLaw_